Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Finished Goods data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Finished Goods fell 14.09% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 14.09% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 1.49% from the prior year.
• Finished Goods for Q1 2026 stood at $1.5 million, up from $1.5 million in the prior quarter.
• Over the last five years, Finished Goods for PHAT reached as high as $2.6 million in Q3 2025 and fell as low as $647000.0 in Q4 2023.
• Historically, Finished Goods has averaged $1.5 million across 4 years, with a median of $1.5 million in 2024.
• Across the five-year window, Finished Goods surged 177.27% in 2025 and declined 14.09% in 2026, its largest moves.
• Year by year, Finished Goods stood at $647000.0 in 2023, then jumped by 128.59% to $1.5 million in 2024, then declined by 1.49% to $1.5 million in 2025, then rose by 1.72% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $2.6 million in Q3 2025.